GSA Capital Partners LLP Acquires New Holdings in Pharvaris N.V. $PHVS

GSA Capital Partners LLP bought a new stake in Pharvaris N.V. (NASDAQ:PHVS) during the second quarter, Holdings Channel.com reports. The firm bought 16,148 shares of the company’s stock, valued at approximately $558,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. CoreCap Advisors LLC acquired a new position in shares of Pharvaris during the second quarter worth $93,000. Seven Fleet Capital Management LP boosted its holdings in shares of Pharvaris by 472.3% during the 1st quarter. Seven Fleet Capital Management LP now owns 316,697 shares of the company’s stock valued at $8,947,000 after acquiring an additional 261,355 shares in the last quarter. DV Trading LLC bought a new stake in Pharvaris during the 1st quarter worth $4,067,000. Stempoint Capital LP grew its position in Pharvaris by 48.4% during the 1st quarter. Stempoint Capital LP now owns 86,637 shares of the company’s stock worth $2,447,000 after acquiring an additional 28,248 shares during the last quarter. Finally, ADAR1 Capital Management LLC increased its holdings in Pharvaris by 23.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 105,528 shares of the company’s stock worth $2,981,000 after purchasing an additional 20,000 shares in the last quarter.

Wall Street Analysts Forecast Growth

PHVS has been the subject of several research reports. Citizens Jmp increased their target price on Pharvaris from $74.00 to $75.00 and gave the company a “market outperform” rating in a research report on Thursday, August 13th. New Street Research set a $60.00 price target on Pharvaris in a report on Friday, August 14th. UBS Group set a $74.00 price objective on Pharvaris in a research note on Wednesday, May 13th. Wall Street Zen lowered shares of Pharvaris from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Finally, Citigroup reiterated a “market outperform” rating on shares of Pharvaris in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Pharvaris currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.08.

Insider Buying and Selling

In other news, insider Anna Nijdam sold 2,670 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $30.87, for a total transaction of $82,422.90. Following the completion of the transaction, the insider directly owned 46,275 shares in the company, valued at $1,428,509.25. This trade represents a 5.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Anne Lesage sold 30,703 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total value of $1,089,649.47. Following the transaction, the insider owned 93,969 shares of the company’s stock, valued at $3,334,959.81. This trade represents a 24.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 121,325 shares of company stock worth $4,270,425. Corporate insiders own 11.84% of the company’s stock.

Pharvaris Stock Up 0.3%

NASDAQ PHVS opened at $36.39 on Friday. The company has a market capitalization of $2.38 billion, a price-to-earnings ratio of -11.93 and a beta of -2.31. Pharvaris N.V. has a twelve month low of $20.65 and a twelve month high of $36.93. The stock has a fifty day simple moving average of $34.06 and a 200 day simple moving average of $30.35.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Research analysts expect that Pharvaris N.V. will post -3.15 earnings per share for the current fiscal year.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.